Search Results

Sonoma Pharmaceuticals, Inc. and its partner, the MicroSafe Group DMCC, are excited to announce that Nanocyn hospital-grade disinfectant has received additional claims from the U.S. Environmental Protection Agency (EPA) for effective use against Methicillin Resistant Staphylococcus Aureus (MRSA), Salmonella, Norovirus, Poliovirus, and as a fungicide

Sonoma Pharmaceuticals, Inc., a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions and disinfectant use, and its partner, the MicroSafe Group DMCC, received EPA approval for Nanocyn® as a hospital-grade disinfectant in the United States.

Sonoma Pharmaceuticals, Inc. and its partner, the MicroSafe Group DMCC, are pleased to announce that Nanocyn® hospital grade disinfectant has been added to the list of COVID-19 disinfectants maintained by the U.S. Environmental Protection Agency’s List N.

Sonoma Pharmaceuticals and MicroSafe Group Announce that Nanocyn ® Disinfectant & Sanitizer Has Been Approved by the Australia TGA with a 15 Second SARS-CoV-2 (COVID-19) Kill Time

Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty pharmaceutical company dedicated to identifying, developing and commercializing unique, differentiated therapies to millions of patients living with chronic skin and wound conditions, is pleased to announce that it successfully closed on an asset purchase agreement for certain wound care, disinfection and animal health care products in the Middle East, Australia and Europe for $1.1 million with MicroSafe Group.

Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care and dermatological conditions, and its partner, the MicroSafe Group, Dubai, announce an important break-through in the fight of the global coronavirus pandemic

The first approval is for Acuicyn eyelid and eyelash hygiene, an antimicrobial solution (hypochlorous acid) indicated to treat symptoms and causes of blepharitis on the eyelid and eyelash.

Sonoma Pharmaceuticals, Inc. announced financial results for fiscal year 2022 and the fourth quarter ended March 31, 2022.